Use of GLP‐1 receptor agonists and subsequent risk of alcohol‐related events. A nationwide register‐based cohort and self‐controlled case series study

Animal studies have related glucagon‐like peptide 1 receptor agonists (GLP‐1) to lower alcohol intake. We examined whether GLP‐1 was associated with risk of alcohol‐related events in a nationwide cohort study and a self‐controlled case series analysis including all new users of GLP1 (n = 38 454) and dipeptidyl peptidase 4 inhibitors (DPP4) (n = 49 222) in Denmark 2009–2017. They were followed for hospital contacts with alcohol use disorder or purchase of drugs for treatment of alcohol dependence in nationwide registers from 2009 to 2018. Associations were examined using Cox proportional hazard and conditional Poisson regression. During follow‐up of median 4.1 years, 649 (0.7%) of participants were registered with an alcohol‐related event. Initiation of GLP‐1 treatment was associated with lower risk of an alcohol‐related event (Hazard ratio = 0.46 (95%CI: 0.24–0.86) compared with initiation of DPP4 during the first 3 months of follow‐up. Self‐controlled analysis showed the highest risk of alcohol‐related events in the 3‐month pretreatment period (incidence rate ratio [IRR] = 1.25 (1.00–1.58)), whereas the risk was lowest in the first 3‐month treatment period (IRR = 0.74 (0.56–0.97). In conclusion, compared with DPP4 users, individuals who start treatment with GLP‐1 had lower incidence of alcohol‐related events both in cohort and self‐controlled analyses. Thus, there might be a transient preventive effect of GLP1 on alcohol‐related events the first months after treatment initiation.